PMV Pharmaceuticals, Inc. (PMVP)

NMS – Real vaqt narxi. Valyuta: USD

1.42

+0.03 (2.16%)

Yopilishda: May 12, 2026, 4:00 PM EDT

1.38

-0.04 (-2.82%)

Bozor oldidan: May 13, 2026, 9:01 AM EDT

22.04.2026

PMV Pharmaceuticals Announces Board Chair Transition

Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair

06.03.2026

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.

24.10.2025

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced updated data from the Phase 2 pivotal portion of the ongoing PYNNACLE clinical trial. Results were presented today in an oral presentation by Alison M. Schram, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts. The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.

07.08.2025

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

07.08.2025

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.

Videolar

No Data

There is no data to display

Press-relizlar

22.04.2026

PMV Pharmaceuticals Announces Board Chair Transition

06.03.2026

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

24.10.2025

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

07.08.2025

PMV Pharmaceuticals, Inc. (PMVP)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Videolar

No Data

Press-relizlar

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Videolar

No Data

Press-relizlar

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Search stocks

PMV Pharmaceuticals, Inc. (PMVP)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Videolar

No Data

Press-relizlar

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

Videolar

No Data

Press-relizlar

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights